Actelion, a part of the Johnson & Johnson Family of Companies, is a global leader in the treatment of pulmonary arterial hypertension (PAH), a serious condition affecting the pulmonary arteries and the right side of the heart. The company has several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods.
Cyborg Score Rationale
Actelion operates as a subsidiary of Johnson & Johnson with a focused, defensible market position in rare diseases, particularly pulmonary arterial hypertension with an established portfolio of approved medications. The company benefits from J&J's resources and distribution while maintaining specialized expertise; however, limited public visibility as a private subsidiary constrains valuation certainty.
Top Insights
Actelion was acquired by Johnson & Johnson (June 2017), providing access to global distribution and R&D resources while maintaining focused rare-disease operations
Actelion also offers treatments for other serious illnesses, including type 1 Gaucher disease, Niemann-Pick type C disease, and digital ulcers in patients with systemic sclerosis, diversifying beyond PAH
Actelion Pharmaceuticals has 2,624 total employees, reflecting a specialized mid-size biotech operation
Multi-modal drug delivery (oral, inhaled, intravenous) across PAH treatments enables differentiated patient outcomes and portfolio depth
Named Competitors
Selexipag/Uptravi competitor products — PAH treatment and lung transplantation support
Recent Developments
(March 2024) Transferred worldwide rights (excluding US/Canada) for PONVORY® multiple sclerosis treatment to Juvissé Pharmaceuticals
(December 2023) Sold rights to Actelion's multiple sclerosis drug to Vanda Pharmaceuticals
(June 2017) Acquired by Johnson & Johnson Innovative Medicine business segment for strategic PAH market consolidation
Open the full interactive Actelion Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.